Adjust assumptions
Adjust the usable peer mix to see how each valuation multiple moves the blended fair value.
Peer-implied fair value
$666.77
Blended value per share under the current mix.
Current price
—
Market price unavailable
Peer gap
N/A
Peer gap unavailable
Weighting mixer
Value contribution
6 peers →Price / Sales
$173.67B
Price / Earnings
$454.00B
Price / Sales
$347.34B
Price / Earnings
$907.99B
Equal-weight baseline
Premium 0.0%The simple average of every usable peer method, before your weighting adjustments.
Baseline equity value
$627.67B
Baseline / share
$666.77
Relative valuation prices this company against what the market already pays for its peers. For a cash-flow view that does not inherit peer sentiment, open the intrinsic model.
Spreadsheet data
Audit the saved peer set and the method inputs behind the blended fair value.
The saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market cap | Enterprise value | Revenue |
|---|
| EBITDA |
|---|
| Net income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
PFE PFIZER INC FY ended Feb 19, 2026 | — | — | — | $62.58B | $15.48B | $7.77B | — | — | — |
MRK Merck & Co., Inc. FY ended Jan 31, 2026 | $144.91 | $357.52B | — | $65.01B | $28.05B | $18.25B | 19.91x | 5.50x | — |
JNJ JOHNSON & JOHNSON FY ended Feb 06, 2026 | — | — | — | $94.19B | $37.95B | $26.80B | — | — | — |
ABBV AbbVie Inc. FY ended Feb 10, 2026 | $262.51 | $463.89B | — | $61.16B | $17.62B | $4.23B | 111.23x | 7.58x | — |
AMGN AMGEN INC FY ended Feb 10, 2026 | $376.35 | $203.47B | — | $36.75B | $14.04B | $7.71B | 26.45x | 5.54x | — |
BMY BRISTOL MYERS SQUIBB CO FY ended Feb 04, 2026 | $63.60 | $129.92B | — | $48.19B | $14.61B | $7.05B | 18.38x | 2.70x | — |
PFE
PFIZER INC
—
—
—
$62.58B
$15.48B
—
—
—
Cap —EV —Rev $62.58BEBITDA $15.48BP/E —P/S —EV/EBITDA —
MRK
Merck & Co., Inc.
$144.91
$357.52B
—
$65.01B
$28.05B
19.91x
5.50x
—
Cap $357.52BEV —Rev $65.01BEBITDA $28.05BP/E 19.91xP/S 5.50xEV/EBITDA —
JNJ
JOHNSON & JOHNSON
—
—
—
$94.19B
$37.95B
—
—
—
Cap —EV —Rev $94.19BEBITDA $37.95BP/E —P/S —EV/EBITDA —
ABBV
AbbVie Inc.
$262.51
$463.89B
—
$61.16B
$17.62B
111.23x
7.58x
—
Cap $463.89BEV —Rev $61.16BEBITDA $17.62BP/E 111.23xP/S 7.58xEV/EBITDA —
AMGN
AMGEN INC
$376.35
$203.47B
—
$36.75B
$14.04B
26.45x
5.54x
—
Cap $203.47BEV —Rev $36.75BEBITDA $14.04BP/E 26.45xP/S 5.54xEV/EBITDA —
BMY
BRISTOL MYERS SQUIBB CO
$63.60
$129.92B
—
$48.19B
$14.61B
18.38x
2.70x
—
Cap $129.92BEV —Rev $48.19BEBITDA $14.61BP/E 18.38xP/S 2.70xEV/EBITDA —
Which peer averages feed the weighted fair value, and which methods are excluded.
| Method | Type | Avg. multiple | Coverage | Implied equity value | Fair value / share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | — | 0/6 | — | — | No saved peers have usable coverage for this method. |
Price / Sales PSActive | Equity Multiple | 5.33x | 4/6 | $347.34B | $368.98 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 43.99x | 4/6 | $907.99B | $964.56 | Included in the active peer mix. |
EV / EBITDA
EV · Enterprise Multiple
Avg. multiple
—
Coverage
0/6
Implied equity value
—
Fair value / share
—
No saved peers have usable coverage for this method.
Price / Sales
PS · Equity Multiple
Avg. multiple
5.33x
Coverage
4/6
Implied equity value
$347.34B
Fair value / share
$368.98
Included in the active peer mix.
Price / Earnings
PE · Equity Multiple
Avg. multiple
43.99x
Coverage
4/6
Implied equity value
$907.99B
Fair value / share
$964.56
Included in the active peer mix.
